Hepatitis B virus reactivation in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization therapy

Asia-Pacific Journal of Clinical Oncology

Volumn 8, Issue 4, 2012, Pages 356-361

  Peng, Jie Wen ^a   Lin, Gui Nan ^a   Xiao, Jian Jun ^a   Jiang, Xiao Mei ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Hepatitis B virus; Hepatocellular carcinoma; Transcatheter arterial chemoembolization; Viral reactivation

Indexed keywords

10 HYDROXYCAMPTOTHECIN; ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; BILIRUBIN; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; MITOMYCIN C; VIRUS DNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CHEMOEMBOLIZATION; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION TEST; MALE; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; QUANTITATIVE ANALYSIS; THERAPY EFFECT; VIRUS REACTIVATION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; ENBUCRILATE; ETHIODIZED OIL; FEMALE; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MITOMYCIN; RETROSPECTIVE STUDIES; VIRUS ACTIVATION;

EID: 84870341838     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2012.01534.x     Document Type: Article

References (11)

1. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43: 209-20.
2. Llovet JM, Real MI, Montaña X etal. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 2002; 359: 1734-9.
3. Jang JW, Choi JY, Bae SH etal. Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J Hepatol 2004; 41: 427-35.
4. Jang JW, Kwon JH, You CR etal. Risk of HBV reactivation according to viral status and treatment intensity in patients with hepatocellular carcinoma. Antivir Ther 2011; 16: 969-77.
5. Rehermann B, Ferrari C, Pasquinelli C etal. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996; 2: 1104-8.
6. Yuki N, Nagaoka T, Yamashiro M etal. Long-term histologic and virologic outcomes of acute self-limited hepatitis B. Hepatology 2003; 37: 1172-9.
7. Yeo W, Chan TC, Leung NWY etal. Reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27: 605-11.
8. Park JW, Park KW, Cho SH etal. Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization therapy for patients with HBV-related hepatocellular carcinoma: report of a prospective study. Am J Gastroenterol 2005; 100: 2194-200.
9. Jang JW, Choi JY, Bae SH etal. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology 2006; 43: 233-40.
10. Hsu C, Hsiung CA, Su IJ etal. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology 2008; 47: 844-53.
11. Bartholomeusz A, Locarnini SA. Antiviral drug resistance. Clinical consequences and molecular aspects. Semin Liver Dis 2006; 26: 162-70.